nonheterogenous patient population [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . We reviewed the frequency and clinical characteristics of CMV pneumonia among all adult nontransplantation patients with cancer and who were autopsied at the University of Texas M. D. Anderson Cancer Center (MDACC; Houston) from 1964 through 1990.
Methods

Patients
All autopsy reports at MDACC from the period of January 1964 through December 1990 were reviewed. Patients who had CMV lung inclusions diagnosed were eligible for the study.
Patients were excluded if they were < 17 years of age, had HIV infection, or were transplant recipients.
Histopathology CMV pneumonia was defined by certain histopathologic criteria: (1) characteristic intranuclear inclusions with surrounding necrosis and/or inflammation and (2) the absence of any other pathogen in the same histologic section [18] . Co-infection with another pathogen in a distant area of the lung was considered to be a mixed infection.
To confirm the presence of CMV disease in these histopathologically diagnosed cases, immunohistochemical studies were performed by means of a modification of a method described by Hsu et al. [19] that detects CMV early and late antigens. Tissue sections were incubated at 4°C with a 1:100 dilution of monoclonal antibodies (Dako, Carpinteria, CA) directed against early and late CMV antigens. Slides were washed in PBS, incubated with an avidin-biotin-labeled antibody, and developed with 3-amino-9-ethyl carbazole (Vector Elite Kit; Vector Laboratories, Burlingame, CA). Positive and negative con-troIs consisted of human CMV·infected and CMV-noninfected lung tissue.
Chart Review
The clinical charts of all eligible patients with CMV pneumonia were reviewed. The clinical and radiographic findings within the initial 72 hours following the onset ofthe respiratory illness were recorded.
Statistical Analysis
Disease-specific rates of CMV were calculated with use of the number of autopsies as a denominator. Since CMV is uncommon in this population, the significance levels for differences between rates and the 95% confidence intervals were computed by means of the Poisson distribution, after the method described by Cox [20] .
Results
From 1964 through 1990, 10,441 autopsies were performed at MDACC; 1,412 autopsies were excluded from the analysis on the basis of the previously mentioned criteria. CMV lung inclusions were noted in 32 of the remaining 9,029 autopsies (3.5 cases per 1,000 autopsies). Twelve of these 32 cases were excluded because of the presence of other pathogens in the same histologic section of the lung as the CMV inclusions (7 cases of bacterial pneumonia); because of intercurrent disease (l case of drug-induced bronchiolitis obliterans and 1 case of tumor infiltration); or because of the absence of surrounding inflammation or necrosis (3 cases). The remaining 20 cases met the histologic criteria for CMV pneumonia.
The mean age of these 20 patients was 41 years (range, 19-70 years), and the male-to-female ratio was 3:2. Fourteen patients had hematologic malignancies and six patients had solid tumors (table 1). All 20 patients had received chemotherapy, 15 patients had received steroids, and 11 patients had received radiotherapy within 30 days of the diagnosis of pneumonia. Immunohistochemical assays confirmed the histopathologic diagnosis of CMV infection in eight of 10 cases studied. One of the two negative cases had been previously confirmed by CMV culture.
Frequency of CMV Pneumonia
The overall rate ofCMV pneumonia was 2.2 cases per 1,000 autopsies (20 of 9,029). Ten cases occurred during [1964] [1965] [1966] [1967] [1968] [1969] [1970] [1971] [1972] [1973] [1974] [1975] [1976] [1977] [1978] [1979] and 10 occurred during 1980-1990 (1.5 and 4.6 cases, respectively, per 1,000 autopsies). The latter rate represented a 3.2-fold increase (P < .05). The rate ofCMV pneumonia increased during the two periods, both among patients with solid tumors and among those with hematologic malignancies. In patients with solid tumors, however, the rate of CMV pneumonia increased from 0.4 to 3.6 cases per 1,000 autopsies (a 9.0-fold increase; P < .05). In patients with hematologic malignancies, the rate increased from 4.2 to 6.9 per 1,000 autopsies (a 1.6-fold increase; P = .18).
The rate of CMV pneumonia per 1,000 autopsies associated with each type of malignancy (classified by primary origin of the tumor) is shown in table 1. The highest rate occurred among patients with multiple myeloma, brain tumor, undifferentiated tumor, and non-Hodgkin's lymphoma (18.4, 10.1, 7.3, and 6.8 cases, respectively, per 1,000 autopsies). When the rate of CMV pneumonia associated with each type of tumor was compared with the rate of CMV pneumonia with the other tumors overall, both non-Hodgkin's lymphoma and multiple myeloma remained statistically significant factors (P < .05), suggesting a real increase in the frequency of CMV pneumonia in patients with these malignancies.
Clinical Presentation of CMV Pneumonia
Although 20 patients met the histologic criteria for CMV pneumonia, eight patients had other abnormalities in sections of lung tissue distant from the area of CMV inclusions. These included tumor invasion (5 cases), bacterial and/or fungal pneumonia (2 cases), and pulmonary embolism (1 case). Although there were no significant differences between the clinical and radiographic presentations of these 8 cases of mixed infection and those of the 12 cases of pure CMV pneumonia, these 8 cases were excluded from the clinical description in order to focus on the features of pure CMV pneumonia.
The signs and symptoms of the 12 cases of pure CMV pneumonia are listed in table 2. The clinical signs were similar in patients with solid tumors and hematologic malignancies. All patients had fever, dyspnea, and tachypnea at clinical presentation. Fever was present for a mean of 14 days (range, 2-42 days) prior to clinical presentation. Basilar crackles were heard in 80% of patients (8/1 0). Arterial blood gas determinations for seven patients revealed a partial pressure of O 2 value of <60 mm Hg. Three patients had a shock syndrome [21] within 72 hours of clinical presentation, but there was no clinicalor microbiological evidence of fungal or bacterial infection. Seven patients required mechanical ventilation within 5 days of the onset of respiratory symptoms.
Radiographs for 11 of the 12 patients were available for evaluation. These revealed bilateral interstitial infiltrates (4 cases), multilobar consolidations (4 cases), unilobar consolidation (2 cases), and no infiltrates (1 case). Bilateral interstitial infiltrates developed in the last patient, but not within the first 72 hours after the clinical onset of illness. When all 20 cases of CMV pneumonia were considered, 14 patients had clinically or microbiologically documented secondary infections before death. No particular microorganism or site of infection predominated. t Confidence intervals for rates of 0 are one-tailed, 97.5% limits.
t P value ofthe rate ofCMV pneumonia with each type of tumor compared with the overall rate ofCMV pneumonia in the other tumors as a group, as determined with use of the method described by Cox [20] . em 1996;22 (June) Autopsy Findings
The diagnosis of CMV pneumonia was not made until autopsy in 19 of 20 cases. CMV pneumonia was considered by the pathologist to be the primary cause of death in 11 cases and contributory in the remaining nine cases. At autopsy (table 3), 11 patients (55%) had disseminated CMV infection. The Table 2 . Clinical and radiographic findings for 12 patients with CMV pneumonia. adrenal glands (33%), liver (28%), gastrointestinal tract (22%), and prostate (20%) were the organs most commonly involved. Five patients had another infection noted at autopsy, but only two patients had a concurrent lung infection (one case each of bacterial pneumonia and mixed bacterial/fungal pneumonia). Seventeen patients (85%) had evidence of malignancy, which was disseminated in 12 cases and localized in five cases. (18) 1 (6) * Present within 72 hours of the onset of respiratory symptoms.
t No. ofpatients for whom such information was noted in the medical record. * No. of patients evaluated with regard to indicated parameter.
Discussion
The objective of this autopsy study was to determine the frequency of CMV disease in adult nontransplantation patients with cancer. Investigators in previous autopsy studies of patients with a wide variety of underlying diseases reported rates of CMV pneumonia of 2.7 to 14.5 cases per 1,000 autopsies [8, 11, 12, 14, 17, 22] . A precise estimate of the incidence of CMV pneumonia in adult nontransplantation patients with cancer has been difficult to determine because of the heterogeneity of the populations studied.
Our study showed that the rate of CMV pneumonia from 1964 through 1990 was 2.3 cases per 1,000 autopsies. The rate was highest among patients with non-Hodgkin's lymphoma and multiple myeloma. Comparison of the period 1964-1979 with the period 1980-1990 showed an increase (3.2-fold) in the rate of CMV pneumonia in both patients with solid tumors and patients with hematologic malignancies, with the greatest increase associated with solid tumors. The statistically significant rise in CMV pneumonia associated with solid tumors vs. hematologic malignancies may reflect a greater change in the degree of immunosuppression in these patients during the past decade. This finding should be interpreted with caution because of the small number of cases involving nonhematologic malignancies.
Since this was an autopsy study, the true frequency ofCMV pneumonia may have been underestimated. Self-limited infections and fatal infections in patients who were not autopsied would have been missed, and additional autopsy cases may have been undiagnosed owing to random sampling of lung tissue [23, 24] . Conversely, the incidence of CMV pneumonia may have been slightly overestimated by the inclusion of cases from between 1978 and 1985, when serological testing for HIV infection was not yet available. This is unlikely to have had much impact on the overall incidence since only two patients had a possible AIDS-identifying illness (lymphoma in both cases). Since it would be uncommon to find CMV as the only opportunistic pathogen at autopsy of a patient with AIDS, it is unlikely that these two patients were infected with HIV [25] .
It is also possible that the higher frequency of CMV pneumonia in the later years reflected a declining frequency of autopsies, from~80% in the 1964-1979 period to~33% in the 1980-1990 period. To the best of our knowledge, however, the indications for autopsy did not change during those two periods, so it is not likely that this was a major factor.
Evaluation of the radiological presentation did not reveal any specific pattern to distinguish CMV pneumonia from other causes of lobar and interstitial infiltrates. The clinical presentation was also nonspecific, a circumstance reflected by the fact that the majority of the cases were diagnosed at autopsy.
The development of new diagnostic techniques using shell vial cultures, antigenemia assays, and PCR has increased our ability to detect early CMV infection. The finding of CMV in a sample of lower respiratory tract secretions from a nontransplantation patient with cancer and who presents with fever, interstitial infiltrates, and low partial arterial pressure of O 2 may become an increasingly common therapeutic dilemma.
Ganciclovir has been shown to have an effect in several different patient populations for the treatment of or prophylaxis for CMV pneumonia, gastrointestinal disease, and retinitis [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . It is difficult to recommend antiviral therapy for adult nontransplantation patients with cancer, even when virus is isolated from the lower respiratory tract, because of the low autopsy incidence of CMV pneumonia in such patients.
In addition, the frequency with which CMV is isolated from the respiratory tracts of these patients is unknown, whether or not they have lower respiratory tract disease. CMV may be isolated from BAL specimens from allogeneic bone marrow transplant recipients without CMV disease [36] . Adult nontransplantation patients with cancer may also shed CMV that is unrelated to their underlying pulmonary process. At this time, a cautious approach to the clinical interpretation of recovery of CMV from respiratory specimens is needed. The advent of new immunosuppressive and chemotherapeutic agents may be associated with a change in the spectrum of opportunistic infections. It is important to continue to reevaluate the incidence of CMV disease in adult nontransplantation patients with cancer.
